Search

Your search keyword '"Buisson, Marlyse"' showing total 37 results
Start Over Author "Buisson, Marlyse"
37 results on '"Buisson, Marlyse"'

1. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

Author

Sulbaran, Guidenn, Maisonnasse, Pauline, Amen, Axelle, Effantin, Gregory, Guilligay, Delphine, Dereuddre-Bosquet, Nathalie, Burger, Judith A., Poniman, Meliawati, Grobben, Marloes, Buisson, Marlyse, Dergan Dylon, Sebastian, Naninck, Thibaut, Lemaître, Julien, Gros, Wesley, Gallouët, Anne-Sophie, Marlin, Romain, Bouillier, Camille, Contreras, Vanessa, Relouzat, Francis, Fenel, Daphna, Thepaut, Michel, Bally, Isabelle, Thielens, Nicole, Fieschi, Franck, Schoehn, Guy, van der Werf, Sylvie, van Gils, Marit J., Sanders, Rogier W., Poignard, Pascal, Le Grand, Roger, and Weissenhorn, Winfried

Published
2022
Full Text
View/download PDF

3. Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform

Author

Chevillard, Christopher, primary, Amen, Axelle, additional, Besson, Solène, additional, Hannani, Dalil, additional, Bally, Isabelle, additional, Dettling, Valentin, additional, Gout, Evelyne, additional, Moreau, Christophe J., additional, Buisson, Marlyse, additional, Gallet, Salomé, additional, Fenel, Daphna, additional, Vassal-Stermann, Emilie, additional, Schoehn, Guy, additional, Poignard, Pascal, additional, Dagher, Marie-Claire, additional, and Fender, Pascal, additional

Published
2022
Full Text
View/download PDF

5. Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

Author

Epaulard, Olivier, primary, Buisson, Marlyse, additional, Nemoz, Benjamin, additional, Maréchal, Marion Le, additional, Terzi, Nicolas, additional, Payen, Jean-François, additional, Froidure, Marie, additional, Blanc, Myriam, additional, Mounayar, Anne-Laure, additional, Quénard, Fanny, additional, Pierre, Isabelle, additional, Pavese, Patricia, additional, Germi, Raphaele, additional, Grossi, Laurence, additional, Larrat, Sylvie, additional, Poignard, Pascal, additional, and Lupo, Julien, additional

Published
2022
Full Text
View/download PDF

6. AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome

Author

Chabert, Clovis, primary, Vitte, Anne-Laure, additional, Iuso, Domenico, additional, Chuffart, Florent, additional, Trocme, Candice, additional, Buisson, Marlyse, additional, Poignard, Pascal, additional, Lardinois, Benjamin, additional, Debois, Régis, additional, Rousseaux, Sophie, additional, Pepin, Jean-Louis, additional, Martinot, Jean-Benoit, additional, and Khochbin, Saadi, additional

Published
2022
Full Text
View/download PDF

8. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection

Author

Sulbaran, Guidenn, primary, Maisonnasse, Pauline, additional, Amen, Axelle, additional, Guilligay, Delphine, additional, Dereuddre-Bosquet, Nathalie, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Buisson, Marlyse, additional, Dergan Dylon, Sebastian, additional, Naninck, Thibaut, additional, Lemaître, Julien, additional, Gros, Wesley, additional, Gallouët, Anne-Sophie, additional, Marlin, Romain, additional, Bouillier, Camille, additional, Contreras, Vanessa, additional, Relouzat, Francis, additional, Fenel, Daphna, additional, Thepaut, Michel, additional, Bally, Isabelle, additional, Thielens, Nicole, additional, Fieschi, Franck, additional, Schoehn, Guy, additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Sanders, Rogier W., additional, Poignard, Pascal, additional, Le Grand, Roger, additional, and Weissenhorn, Winfried, additional

Published
2021
Full Text
View/download PDF

10. Clinical and microbiological assessments of COVID-19 in healthcare workers: a prospective longitudinal study

Author

Bal, Antonin, primary, Brengel-Pesce, Karen, additional, Gaymard, Alexandre, additional, Quéromès, Grégory, additional, Guibert, Nicolas, additional, Frobert, Emile, additional, Bouscambert, Maude, additional, Trabaud, Mary-Anne, additional, Allantaz-Frager, Florence, additional, Oriol, Guy, additional, Cheynet, Valérie, additional, d’Aubarede, Constance, additional, Massardier-Pilonchery, Amélie, additional, Buisson, Marlyse, additional, Lupo, Julien, additional, Pozzetto, Bruno, additional, Poignard, Pascal, additional, Lina, Bruno, additional, Fassier, Jean-Baptiste, additional, Morfin-Sherpa, Florence, additional, and Trouillet-Assant, Sophie, additional

Published
2020
Full Text
View/download PDF

11. Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.

Author

Bal, Antonin, Brengel-Pesce, Karen, Gaymard, Alexandre, Quéromès, Grégory, Guibert, Nicolas, Frobert, Emile, Bouscambert, Maude, Trabaud, Mary-Anne, Allantaz-Frager, Florence, Oriol, Guy, Cheynet, Valérie, d'Aubarede, Constance, Massardier-Pilonchery, Amélie, Buisson, Marlyse, Lupo, Julien, Pozzetto, Bruno, Poignard, Pascal, Lina, Bruno, Fassier, Jean-Baptiste, and Morfin, Florence

Subjects
COVID-19, MEDICAL personnel, VIRAL load, VIRUS cultures & culture media, REVERSE transcriptase polymerase chain reaction
Abstract

A comprehensive clinical and microbiological assessments of COVID-19 in front-line healthcare workers (HCWs) is needed. Between April 10th and May 28th, 2020, 319 HCWs with acute illness were reviewed. In addition to SARS-CoV-2 RT-PCR screening, a multiplex molecular panel was used for testing other respiratory pathogens. For SARS-CoV-2 positive HCWs, the normalized viral load, viral culture, and virus neutralization assays were performed weekly. For SARS-CoV-2 negative HCWs, SARS-CoV-2 serological testing was performed one month after inclusion. Among the 319 HCWs included, 67 (21.0%) were tested positive for SARS-CoV-2; 65/67 (97.0%) developed mild form of COVID-19. Other respiratory pathogens were found in 6/66 (9.1%) SARS-CoV-2 positive and 47/241 (19.5%) SARS-Cov-2 negative HCWs (p = 0.07). The proportion of HCWs with a viral load > 5.0 log10 cp/mL (Ct value < 25) was less than 15% at 8 days after symptom onset; 12% of HCWs were positive after 40 days (Ct > 37). More than 90% of cultivable virus had a viral load > 4.5 log10 cp/mL (Ct < 26) and were collected within 10 days after symptom onset. Among negative HCWs, 6/190 (3.2%) seroconverted. Our data suggest that the determination of viral load can be used for appreciating the infectiousness of infected HCWs. These data could be helpful for facilitating their return to work. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD

Author

Habib, Mohammed, primary, Buisson, Marlyse, additional, Lupo, Julien, additional, Agbalika, Felix, additional, Socié, Gérard, additional, Germi, Raphaele, additional, Baccard, Monique, additional, Imbert-Marcille, Berthe-Marie, additional, Dantal, Jacques, additional, Morand, Patrice, additional, and Drouet, Emmanuel, additional

Published
2017
Full Text
View/download PDF

13. Ensemble Structure of the Highly Flexible Complex Formed between Vesicular Stomatitis Virus Unassembled Nucleoprotein and its Phosphoprotein Chaperone

Author

Yabukarski, Filip, primary, Leyrat, Cedric, additional, Martinez, Nicolas, additional, Communie, Guillaume, additional, Ivanov, Ivan, additional, Ribeiro, Euripedes A., additional, Buisson, Marlyse, additional, Gerard, Francine C., additional, Bourhis, Jean-Marie, additional, Jensen, Malene Ringkjøbing, additional, Bernadó, Pau, additional, Blackledge, Martin, additional, and Jamin, Marc, additional

Published
2016
Full Text
View/download PDF

18. Publisher Correction: Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.

Author

Bal, Antonin, Brengel-Pesce, Karen, Gaymard, Alexandre, Quéromès, Grégory, Guibert, Nicolas, Frobert, Emilie, Bouscambert, Maude, Trabaud, Mary-Anne, Allantaz-Frager, Florence, Oriol, Guy, Cheynet, Valérie, d'Aubarede, Constance, Massardier-Pilonchery, Amélie, Buisson, Marlyse, Lupo, Julien, Pozzetto, Bruno, Poignard, Pascal, Lina, Bruno, Fassier, Jean-Baptiste, and Morfin, Florence

Subjects
MEDICAL personnel, COVID-19, PUBLISHING, COHORT analysis, LONGITUDINAL method, PATHOLOGICAL laboratories
Abstract

In addition, in the Introduction, "To improve the clinical management of SARS-CoV-2 infection in HCWs, a virological investigation including quantitative RT-PCR, viral culture, as well as the determination of neutralizing antibodytiters over the course of the disease is needed." now reads: "To improve the clinical management of SARS-CoV-2 infection in HCWs, a virological investigation including quantitative RT-PCR, viral culture, as well as the determination of neutralizing antibody titers over the course of the disease is needed." Correction to: I Scientific Reports i https://doi.org/10.1038/s41598-021-93828-y, published online 22 July 2021 The original version of this Article contained an error in the spelling of the author Emilie Frobert which was incorrectly given as Emile Frobert. [Extracted from the article]

Published
2021
Full Text
View/download PDF

19. Inhibition of Epstein–Barr virus replication by small interfering RNA targeting the Epstein–Barr virus protease gene

Author

Larrat, Sylvie, primary, Morand, Patrice, additional, Bas, Ariane, additional, Vigne, Solenne, additional, Crance, Jean-Marc, additional, Boyer, Véronique, additional, Nicod, Sandrine, additional, Grossi, Laurence, additional, Buisson, Marlyse, additional, Burmeister, Wim P, additional, Seigneurin, Jean-Marie, additional, and Germi, Raphaële, additional

Published
2008
Full Text
View/download PDF

25. Hepatitis C virus–Epstein‐barr virus interaction in patients with AIDS

Author

Challine, Dominique, primary, Buisson, Marlyse, additional, Cadilhac, Michel, additional, Germanidis, Georgios, additional, Joab, Irene, additional, Eliaszewicz, Muriel, additional, Caumes, Eric, additional, Flahault, Antoine, additional, Fillet, Anne‐Marie, additional, Pawlotsky, Jean‐Michel, additional, and Seigneurin, Jean‐Marie, additional

Published
2002
Full Text
View/download PDF

27. Functional determinants of the Epstein-Barr virus protease

Author

Buisson, Marlyse, primary, Valette, Erika, additional, Hernandez, Jean-François, additional, Baudin, Florence, additional, Ebel, Christine, additional, Morand, Patrice, additional, Seigneurin, Jean-Marie, additional, Arlaud, Gérard J., additional, and Ruigrok, Rob W.H., additional

Published
2001
Full Text
View/download PDF

28. Human Herpesvirus 8 and Epstein Barr-Virus in a Cutaneous B-Cell Lymphoma and a Malignant Cell Line Established from the Blood of an AIDS Patient

Author

Morand, Patrice, primary, Buisson, Marlyse, additional, Collandre, Helene, additional, Chanzy, Bruno, additional, Genoulaz, Odile, additional, Bourgeat, Marie-Joseite, additional, Pinel, Nicole, additional, Leclercq, Pascale, additional, Leroux, Dominique, additional, Marechal, Vincent, additional, Fritsch, Laurent, additional, Ruigrok, Rob, additional, and Seigneurin, Jean-Marie, additional

Published
1999
Full Text
View/download PDF

32. Inhibition of Epstein–Barr virus replication by small interfering RNA targeting the Epstein–Barr virus protease gene

Author

Larrat, Sylvie, Morand, Patrice, Bas, Ariane, Vigne, Solenne, Crance, Jean-Marc, Boyer, Véronique, Nicod, Sandrine, Grossi, Laurence, Buisson, Marlyse, Burmeister, Wim P, Seigneurin, Jean-Marie, and Germi, Raphaële

Abstract

Background The Epstein–Barr virus (EBV) protease (PR), coded by the BVRF2gene, is essential for the maturation of the viral capsid and viral DNA packaging during the late stage of the EBV lytic cycle. Like the other herpesvirus serine PRs, EBV PR could be a target for the inhibition of EBV replication. To date, no data have been reported on the inhibition of EBV PR messenger RNA (mRNA) by small interfering RNA (siRNA).Methods In this study, siRNAs targeting EBV PR were delivered to the epithelial 293 cell line stably transfected with the complete B95-8 EBV episome. EBV DNA and PR mRNA were quantified by real-time PCR in cells and supernatant, protein expression was assessed by immunoblotting, and production of EBV infectious particles in the culture medium was measured by Raji cell superinfection.Results The EBV PR mRNA within the cells was reduced by 73%, the PR protein by 35% and the amount of virus in the cell supernatant was drastically decreased by 86% or 95%, depending on the method.Conclusions The strong effect of the siRNA targeting EBV PR on EBV replication attests to the crucial role played by EBV PR in the production of infectious particles and suggests that targeting this enzyme can be a new strategy against EBV-associated diseases where virus replication occurs.

Published
2009
Full Text
View/download PDF

33. Hepatitis C virus–Epstein-barr virus interaction in patients with AIDS

Author

Challine, Dominique, Buisson, Marlyse, Cadilhac, Michel, Germanidis, Georgios, Joab, Irene, Eliaszewicz, Muriel, Caumes, Eric, Flahault, Antoine, Fillet, Anne-Marie, Pawlotsky, Jean-Michel, and Seigneurin, Jean-Marie

Abstract

Immortalization of B cells by Epstein-Barr virus (EBV) and their subsequent proliferation leads to B-cell non-Hodgkin's lymphoma in immunocompromised patients. The role of hepatitis C virus (HCV) in B-cell non-Hodgkin's lymphoma has recently been raised, and an interaction between HCV and EBV is supported by recent in vitro experiments. The aim of this study was to investigate in vivo interactions between HCV and EBV in patients with AIDS, i.e., patients exposed to the risk of EBV-related B-cell non-Hodgkin's lymphoma. A total of 135 patients were prospectively studied. Serological and molecular markers of HCV, EBV, and human immunodeficiency virus (HIV) infection were sought. All the patients harbored latent EBV infection, and 20% had detectable HCV RNA in serum. No significant relationship was found between HIV, HCV, and EBV viral load in peripheral blood mononuclear cells or plasma. There was no difference between anti-HCV-positive and -negative patients or between HCV RNA-positive and -negative patients with regard to the prevalence of EBV markers, especially EBV replication markers. The presence of EBV replication markers was not related to HCV RNA seropositivity or to HCV viral load. Five patients subsequently developed B-cell non-Hodgkin's lymphoma, none of whom had markers of EBV or HCV replication. These results argue against an in vivo interaction between HCV and EBV in patients with AIDS, and against a role of HCV infection in the occurrence of B-cell non-Hodgkin's lymphoma in these patients. J. Med. Virol. 67:510–515, 2002. © 2002 Wiley-Liss, Inc.

Published
2002
Full Text
View/download PDF

34. T-Cell Death by Apoptosis in Vertically Human Immunodeficiency Virus-Infected Children Coincides With Expansion of CD8+/Interleukin-2 Receptor/HLA-DR+T Cells: Sign of a Possible Role for Herpes Viruses as Cofactors?

Author

Lauener, Roger P., Hüttner, Silke, Buisson, Marlyse, Hossle, Johann P., Albisetti, Manuela, Seigneurin, Jean-Marie, Seger, Reinhard A., and Nadal, David

Abstract

One mechanism proposed to play a role in T-cell depletion in human immunodeficiency virus (HIV) infection is apoptosis (activation-induced cell death). We assessed whether apoptosis is related to activation of T cells in vivo and its possible triggers. DNA was extracted from peripheral blood mononuclear cells (PBMC) taken from 16 vertically HIV-infected children and 9 HIV-negative children born to HIV-positive mothers (controls) and tested by agarose gel electrophoresis for the presence of DNA fragments specific for apoptosis. Signs of apoptosis were found on in vitro culture of PBMC from 12 of 16 HIV-infected children, but not in PBMC from the nine controls. Eleven of the 12 HIV-infected children with apoptosis showed an elevated (>15%) proportion of CD3+/HLA-DR+ cells. This was due to an increased proportion of CD8+/HLA-DR+cells, as shown in 7 of 7 further tested patients. In none of the probands an increased (>5%) proportion of IL-2 receptor expressing CD3+cells was found. T cells undergoing apoptosis were preferentially of the CD8+phenotype. Expansion of circulating CD8+/interleukin-2 receptor (IL-2R) /HLA-DR+T cells is known to occur during active infection with herpes viruses. To investigate the possible role of herpes viral coinfections for apoptosis in HIV infection, we focused on Epstein-Barr virus (EBV) as an example for a herpes virus usually acquired during childhood. In 10 of 12 patients with apoptosis, we found increased levels of EBV genome in PBMC and/or tissues, indicating active EBV replication. By contrast, no increased burden of EBV was found in the four HIV-infected patients without apoptosis or in the controls. Our data indicate that in children the occurrence of apoptosis in HIV infection is closely related to activation of CD8+T cells. Furthermore, primoin-fection with or reactivation of herpes viruses, such as EBV, may substantially contribute to such T-cell activation and the ensuing apoptosis. Additional studies are warranted to evaluate the contribution of herpes virus-triggered apoptosis to the T-cell loss leading to the acquired immunodeficiency syndrome.

Published
1995
Full Text
View/download PDF

36. EBV Lytic-Phase Protein BGLF5 Contributes to TLR9 Downregulation during Productive Infection.

Author

Michiel van Gent, Griffin, Bryan D., Berkhoff, Eufemia G., van Leeuwen, Daphne, Boer, Ingrid G. J., Buisson, Marlyse, Hartgers, Franca C., Burmeister, Wim P., Wiertz, Emmanuel J., and Ressing, Maaike E.

Subjects
*EPSTEIN-Barr virus, *IMMUNE response, *HERPESVIRUS diseases, *PATHOGENIC microorganisms, *NATURAL immunity
Abstract

Viruses use a wide range of strategies to modulate the host immune response. The human gammaherpesvirus EBV, causative agent of infectious mononucleosis and several malignant tumors, encodes proteins that subvert immune responses, notably those mediated by T cells. Less is known about EBV interference with innate immunity, more specifically at the level of TLR-mediated pathogen recognition. The viral dsDNA sensor TLR9 is expressed on B cells, a natural target of EBV infection. Here, we show that EBV particles trigger innate immune signaling pathways through TLR9. Furthermore, using an in vitro system for productive EBV infection, it has now been possible to compare the expression of TLRs by EBV- and EBV+ human B cells during the latent and lytic phases of infection. Several TLRs were found to be differentially expressed either in latently EBV-infected cells or after induction of the lytic cycle. In particular, TLR9 expression was profoundly decreased at both the RNA and protein levels during productive EBV infection. We identified the EBV lytic-phase protein BGLF5 as a protein that contributes to downregulating TLR9 levels through RNA degradation. Reducing the levels of a pattern-recognition receptor capable of sensing the presence of EBV provides a mechanism by which the virus could obstruct host innate antiviral responses. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

37. New insights on the role of the gamma-herpesvirus uracil-DNA glycosylase leucine loop revealed by the structure of the Epstein-Barr virus enzyme in complex with an inhibitor protein.

Author

Géoui T, Buisson M, Tarbouriech N, and Burmeister WP

Subjects
Amino Acid Motifs, Amino Acid Sequence, Base Sequence, Gammaherpesvirinae chemistry, Herpesvirus 4, Human chemistry, Leucine chemistry, Models, Molecular, Molecular Sequence Data, Molecular Structure, Protein Structure, Secondary, Protein Structure, Tertiary, Sequence Homology, Amino Acid, Structure-Activity Relationship, Gammaherpesvirinae enzymology, Herpesvirus 4, Human enzymology, Uracil-DNA Glycosidase chemistry, Viral Proteins chemistry
Abstract

Epstein-Barr virus (EBV) is a human gamma-herpesvirus. Within its 86 open reading frame containing genome, two enzymes avoiding uracil incorporation into DNA can be found: uracil triphosphate hydrolase and uracil-DNA glycosylase (UNG). The latter one excises uracil bases that are due to cytosine deamination or uracil misincorporation from double-stranded DNA substrates. The EBV enzyme belongs to family 1 UNGs. We solved the three-dimensional structure of EBV UNG in complex with the uracil-DNA glycosylase inhibitor protein (Ugi) from bacteriophage PBS-2 at a resolution of 2.3 A by X-ray crystallography. The structure of EBV UNG encoded by the BKRF3 reading frame shows the excellent global structural conservation within the solved examples of family 1 enzymes. Four out of the five catalytic motifs are completely conserved, whereas the fifth one, the leucine loop, carries a seven residue insertion. Despite this insertion, catalytic constants of EBV UNG are similar to those of other UNGs. Modelling of the EBV UNG-DNA complex shows that the longer leucine loop still contacts DNA and is likely to fulfil its role of DNA binding and deformation differently than the enzymes with previously solved structures. We could show that despite the evolutionary distance of EBV UNG from the natural host protein, bacteriophage Ugi binds with an inhibitory constant of 8 nM to UNG. This is due to an excellent specificity of Ugi for conserved elements of UNG, four of them corresponding to catalytic motifs and a fifth one corresponding to an important beta-turn structuring the catalytic site.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results